文献速递系统性红斑狼疮

系统性红斑狼疮临床试验中人群代表性不公平的系统综述

Systematic Review of Inequitable Population Representation in Systemic Lupus Erythematosus Clinical Trials.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-08-01

该系统性综述与Meta分析评估美国系统性红斑狼疮(SLE)临床试验中历史上被边缘化人群的参与情况,检索MEDLINE与Embase(2024年5月),纳入2018年1月1日至2023年12月31日发表的18项美国SLE临床试验。结果显示性别代表性准确,但11/18项研究(61.1%)的种族与民族参与总体评级为差,无研究获好评,14/18项(77.8%)显示黑人、亚裔和西班牙裔人群的代表性不足未达统计学显著,且无研究报告纳入老年人。

要点

  • 18项美国SLE临床试验中,11项(61.1%)种族与民族参与总体评级为差,无研究获好评。
  • 14项(77.8%)研究显示黑人、亚裔和西班牙裔人群代表性不足未达统计学显著。
  • 无研究报告样本中纳入老年人,提示年龄代表性存在显著需求。

核心结论

  • 研究结果揭示SLE临床试验中疾病人群代表性存在差异,强调黑人、亚裔和西班牙裔及拉丁裔参与者纳入不足以及白人参与者不成比例地过度代表。
  • 研究强调需要启动有效策略以促进历史上被边缘化人群参与SLE临床试验。
  • 解决这些差距对于优先考虑不公平人群的参与、提高SLE治疗标准化以及改善SLE研究相关性是必要的。

研究设计与样本

  • 系统性综述与Meta分析,综合检索MEDLINE(PubMed)和Embase(Elsevier)于2024年5月进行,纳入2018年1月1日至2023年12月31日发表的美国SLE临床试验,由两名评审员通过标准化Google表单独立筛选和提取数据,最终评估18项试验的参与者性别、年龄、种族和民族数据。

主要发现

  • 对性别和社会性别的分析显示,纳入人群准确代表了疾病人群。
  • 关于种族和民族参与,18项研究中有11项(61.1%)获得总体差评,且无研究获得好评。
  • 分析显示,18项研究中有14项(77.8%)表明黑人、亚裔和西班牙裔人群的代表性不足未达统计学显著。
  • 无研究报告样本中纳入老年人,提示年龄代表性存在显著需求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the participation of historically marginalized populations in systemic lupus erythematosus (SLE) clinical trials conducted in the United States. METHODS: SLE, a complex autoimmune disease characterized by a dysregulated immune response leading to inflammation and tissue damage in multiple organ systems, exhibits a mortality rate four times higher in historically marginalized populations compared to the general population. It is essential for clinical trials to accurately represent the disease population to effectively evaluate treatment modalities. However, the current trial design lacks appropriate representation of historically marginalized populations, limiting the generalizability of results. Our study addresses this research gap by evaluating the participant demographics in SLE clinical trials. Relevant clinical trials were obtained in a comprehensive search of MEDLINE (PubMed) and Embase (Elsevier) in May 2024. Included trials were published in the United States between January 1, 2018, and December 31, 2023. Two reviewers independently performed screening and data extraction via a standardized Google Form. RESULTS: Having met our inclusion criteria, 18 US SLE clinical trials were evaluated for participant sex, age, racial, and ethnic data. Analysis of sex and gender revealed that the included population accurately represented the disease population. Regarding race and ethnicity participation, 11 of 18 studies (61.1%) received an overall poor rating, and none received a good rating. Analysis revealed that 14 of 18 studies (77.8%) demonstrated statistically insignificant underrepresentation of Black, Asian, and Hispanic populations. No studies reported the inclusion of older adults in their sample, suggesting a significant need for better age representation. CONCLUSION: The results of this study reveal disparities in the representation of the SLE disease population in clinical trials, emphasizing insufficient inclusion of Black, Asian, and Hispanic and Latino participants and the disproportionate overrepresentation of White participants. Our study highlights the need for the initiation of effective strategies to engage historically marginalized populations in SLE clinical trials. Addressing these gaps is necessary to prioritize the participation of inequitable populations, increase standardization of SLE treatments, and improve the relevance of SLE research.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Sims S, Rowsey K, Hemmerich C, et al. Systematic Review of Inequitable Population Representation in Systemic Lupus Erythematosus Clinical Trials. Arthritis Care Res (Hoboken). 2025. PMID: 40438917. doi:10.1002/acr.25576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。